Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. - Test2 - elhamkhani - TriplyDB

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

http://www.wikidata.org/entity/Q34543009

about

Diabetes Dyslipidemia Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes SLC transporters as therapeutic targets: emerging opportunities Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients

P2860

Q26750905-85B2BB65-8AD6-403A-A4A0-F51DBAF503F4 Q26773558-F2CC64E6-3019-4AC6-B1FD-2FEB15629D17 Q26777529-EED99FB1-50E7-4C7B-AA36-4865526C3FAE Q26864336-F83B8176-03CE-408C-9D44-688C04A6BA19 Q27014726-F1B0FB24-9835-4FA2-B915-EBEBAB1540AB Q28072339-D973F3B8-5995-4929-94DD-2C49FE2DDD68 Q28072765-D554C269-3310-4500-A6AD-028E29021333 Q28080114-0FFF55AE-1BD4-4E4D-A724-756F9AB29DAD Q28553482-A5E79799-4079-4972-BA30-AE87AA0335F2 Q30248634-AEA9F915-5AF6-4B28-84AD-B4279DD036E2 Q32186373-C110861C-B339-4FE1-9588-6756C40A489E Q33567077-5C81E1F1-83A5-448B-B82B-A89FF2DF9629 Q33759610-4B8810B9-A056-40C7-AC9E-ED7E572AA5EB Q33781497-C9FACE38-340F-4A53-848E-C6B44444A9BF Q34105064-4D9A4774-10E3-488F-99DC-76A6D26F1A96 Q34161881-8D41864B-ACB5-4EDF-B220-39567382729A Q34198692-C5FAB5AA-4B1D-4FAD-97C1-B04365E90C1A Q34264365-659B9E47-8609-4D53-B754-2C799407C050 Q34699217-96EE110B-83A4-4934-AD00-C0C5E8EFBCB3 Q34973750-D8CA6B4F-4512-4DAF-9BDC-143E3C8ACED3 Q35548033-1C5C4554-7477-4EE0-B97C-A3D240D0DE24 Q35831426-5D47A74A-08D6-4855-AC3D-AFDBE36F2FB3 Q35973246-C1C646A6-E911-4257-B689-2DEE6F834989 Q35973288-B38B213F-7168-4F18-AAD7-3328DADBFCD9 Q36058592-135E8639-F5B1-487B-B3B2-DE81A8C9211E Q36073442-FDA3D312-1509-4782-A0DD-B02DCF919316 Q36277977-A788AF99-AC5F-46DF-B5A3-7447CEEF74FC Q36317577-6A80C76B-B6F2-4361-80E5-0CE2ABCDCAF1 Q36345951-884EAAAE-F588-4BB4-AF76-05FDC8FD05CE Q36431654-C9EBCA6C-2BFC-4211-9C8F-011248B65914 Q36431670-C84C3521-648A-4CF7-ADEF-B45F681D6FE9 Q36550270-1EF6CDDE-ECDF-4406-9E0A-E1CD73A57AF2 Q36592820-C03430F1-F6F6-40D3-B109-9CF430224B78 Q36709118-AB46E0D2-CC4C-48CB-9FA8-93B2E82BA3F3 Q36762696-3549CD25-87AE-4AEF-A708-39346D2D16CD Q36765350-E72767E4-F94C-4ECB-9367-0147906E934A Q36813327-95201CF8-2C80-40FD-AC0B-63859F45254A Q36867463-2065FACB-6865-4040-A629-94206FCCCE57 Q37030680-388A8E07-92BA-46E9-8FDE-DEFAD6BEBB82 Q37114983-C6FA3BC9-1665-4529-96BF-CB11B6452436

P2860

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

http://www.wikidata.org/entity/Q34543009

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@ast

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@en

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@nl

type

label

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@ast

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@en

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@nl

prefLabel

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@ast

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@en

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@nl

P1433

Q34543009-2F8F6E91-E0D0-402B-82E8-1EFC903EB70F

P1476

Q34543009-2D7AD810-7E76-4CE0-B27A-C354A57D7212

P2093

Q34543009-049E38A1-3F16-4D58-A2B0-4014569B4D24

Q34543009-0F6EC889-5C02-458C-BF5E-5247BDFF9128

Q34543009-36F33925-1955-4B92-8DF1-D16A8A58A9D6

Q34543009-42F26F48-AEFD-4BBF-951D-92797036697B

Q34543009-472AD2D1-C441-4513-805F-D863E8FB08BB

Q34543009-4C165F0D-1241-4211-9D36-D7F908D27642

Q34543009-4CEE09DF-22D4-4DD8-8D25-5A9D8B417EA8

P2860

Q34543009-033FB079-8433-4A55-8D94-ACF3A0695A99

Q34543009-0B2CA040-3C16-498C-8D19-DD7B1FA5ECDA

Q34543009-11632D15-86AC-42C1-B283-CFE04D38CC58

Q34543009-28D7A833-5857-42AF-84C0-7F436BB84B33

Q34543009-44AD5302-45C1-487C-A337-2A6E4585E794

Q34543009-47027FEC-EAC9-4F59-8845-7D1CCF906667

Q34543009-4AB5E31F-C6A1-4753-8719-6F05FFAE1027

Q34543009-52EA79ED-F9FE-4A58-88D2-CC188C6F7306

Q34543009-6FDE9F94-BF60-404A-9C08-4D4DD27A2275

Q34543009-73324E73-D582-4594-875C-C997CB85BA0A

P304

Q34543009-22653C5C-856F-42DC-AF1F-38D78B319EBE

P31

Q34543009-005A9345-7404-4911-AC90-36351500B7B5

P356

Q34543009-EDAF30D6-5B33-4991-AE76-A0543C1607B7

P433

Q34543009-06FA03D8-62D9-4001-80DB-0275E051A7FB

P478

Q34543009-CBCA7B21-A9FF-44B8-A3A5-2BC222889591

P577

Q34543009-3F4FB2CB-B666-4951-A4E0-3B2D791EDFCC

P5875

Q34543009-F4F6815E-1D65-475C-A7EA-2F2CD5D5B001

P698

Q34543009-34797E60-B5AB-4851-BAC2-8F304436D2FA

P921

Q34543009-124DA9AF-9E3D-4756-827C-5FD85580A64B

Q34543009-2B9AB2AB-096E-4CC4-8F3B-E3D30789A6C0

Q34543009-4DD186F9-4CCF-4F5B-AB90-971F00F79619

P932

Q34543009-8F09D515-8D7D-4E08-A34F-8C52C28AE479

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Efficacy and safety of canagli ...... nd metformin and pioglitazone.

@en

P2093

G Meininger

http://www.w3.org/2001/XMLSchema#string

J Yee

http://www.w3.org/2001/XMLSchema#string

P Stein

http://www.w3.org/2001/XMLSchema#string

R Goldenberg

http://www.w3.org/2001/XMLSchema#string

R Guthrie

http://www.w3.org/2001/XMLSchema#string

T Forst

http://www.w3.org/2001/XMLSchema#string

U Vijapurkar

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Standards of medical care in diabetes--2013

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

P304

467-477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12273

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260216472

http://www.w3.org/2001/XMLSchema#string

P698

24528605

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4237547

http://www.w3.org/2001/XMLSchema#string